請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4881
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭守夏 | |
dc.contributor.author | Cheng-Yi Lee | en |
dc.contributor.author | 李政益 | zh_TW |
dc.date.accessioned | 2021-05-14T17:49:30Z | - |
dc.date.available | 2017-03-12 | |
dc.date.available | 2021-05-14T17:49:30Z | - |
dc.date.copyright | 2015-03-12 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-01-13 | |
dc.identifier.citation | American Medical Association. (2005). Guidelines for Pay-for-Performance Programs. Retrieved August 16, 2011
Anderson, G. F. (2003). Physician, public, and policymaker perspectives on chronic conditions. Arch Intern Med, 163(4), 437-442. Bardach, N. S., Wang, J. J., De Leon, S. F., Shih, S. C., Boscardin, W. J., Goldman, L. E., & Dudley, R. A. (2013). Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA, 310(10), 1051-1059. doi: 10.1001/jama.2013.277353 Bodenheimer, T. S., & Grumbach, K. (1996). Capitation or decapitation - Keeping your head in changing times. Jama-Journal of the American Medical Association, 276(13), 1025-1031. Borgdorff, M. W., Sebek, M., Geskus, R. B., Kremer, K., Kalisvaart, N., & van Soolingen, D. (2011). The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol, 40(4), 964-970. doi: 10.1093/ije/dyr058 Brewer, T. F., & Heymann, S. J. (2004). To control and beyond: moving towards eliminating the global tuberculosis threat. J Epidemiol Community Health, 58(10), 822-825. doi: 10.1136/jech.2003.008664 Burman, W. J., Dalton, C. B., Cohn, D. L., Butler, J. R., & Reves, R. R. (1997). A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest, 112(1), 63-70. Burman, W. J., Dalton, C. B., Cohn, D. L., Butler, J. R. G., & Reves, R. R. (1997). A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest, 112(1), 63-70. Campbell, S. M., Reeves, D., Kontopantelis, E., Sibbald, B., & Roland, M. (2009). Effects of pay for performance on the quality of primary care in England. N Engl J Med, 361(4), 368-378. doi: 10.1056/NEJMsa0807651 Campbell, S. M., Scott, A., Parker, R. M., Naccarella, L., Furler, J. S., Young, D., & Sivey, P. M. (2010). Implementing pay-for-performance in Australian primary care: lessons from the United Kingdom and the United States. Med J Aust, 193(7), 408-411. Chang, R. E., Lin, S. P., & Aron, D. C. (2012). A pay-for-performance program in Taiwan improved care for some diabetes patients, but doctors may have excluded sicker ones. Health Aff (Millwood), 31(1), 93-102. doi: 10.1377/hlthaff.2010.0402 Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 40(5), 373-383. Chaulk, C. P., & Kazandjian, V. A. (1998). Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA, 279(12), 943-948. Chen, T. T., Chung, K. P., Lin, I. C., & Lai, M. S. (2011). The unintended consequence of diabetes mellitus pay-for-performance (P4P) program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program? Health Services Research, 46(1 Pt 1), 47-60. doi: 10.1111/j.1475-6773.2010.01182.x Cheng, S. H., Lee, T. T., & Chen, C. C. (2012). A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment. Med Care, 50(2), 109-116. doi: 10.1097/MLR.0b013e31822d5d36 Chernichovsky, D. (2000). The Public-Private Mix in the Modern Health Care System - Concepts, Issues, and Policy Options Revisited. Cambridge, MA: National Bureau of Economic Research. Chiang, C. Y., Enarson, D. A., Yang, S. L., Suo, J., & Lin, T. P. (2002). The impact of national health insurance on the notification of tuberculosis in Taiwan. Int J Tuberc Lung Dis, 6(11), 974-979. China Tuberculosis Control, C. (2004). The effect of tuberculosis control in China. Lancet, 364(9432), 417-422. doi: 10.1016/S0140-6736(04)16764-0 Chowdhury, A. M., Chowdhury, S., Islam, M. N., Islam, A., & Vaughan, J. P. (1997). Control of tuberculosis by community health workers in Bangladesh. Lancet, 350(9072), 169-172. doi: 10.1016/S0140-6736(96)11311-8 Christianson, J. B., Leatherman, S., & Sutherland, K. (2008). Lessons from evaluations of purchaser pay-for-performance programs: a review of the evidence. Med Care Res Rev, 65(6 Suppl), 5S-35S. doi: 10.1177/1077558708324236 Chuang, J. C. C., Kuo HS. (2006). Web-based tools help fight TB in Taiwan. Paper presented at the 11 th World Congress on Internet in Medicine, Madnet. Crowe, S. (1997). DOTS is effective even in nomadic populations. Lancet, 350(9074), 343-343. Dean T Jamison, J. G. B., Anthony R Measham, George Alleyne, Mariam Claeson, David B Evans, Prabhat Jha, Anne Mills, and Philip Musgrove. (2006). Disease Control Priorities in Developing Countries (2nd edition ed.). Washington (DC): World Bank. Detsky, A. S., Wodchis, W. P., & Ross, J. S. (2007). Is P4P really FFS? Jama-Journal of the American Medical Association, 298(15), 1797-1799. Doran, T., Fullwood, C., Gravelle, H., Reeves, D., Kontopantelis, E., Hiroeh, U., & Roland, M. (2006). Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med, 355(4), 375-384. doi: 10.1056/NEJMsa055505 Drummond MF., S. M., Torrance GW., O’Brien BJ, Stoddart GL. (2005). Methods for the Ecomomic Evaluation of Health Care Programme (Third Edition ed. Vol. Oxford): London. Dudley, R. A., Frolich, A., Robinowitz, D. L., Talavera, J. A., Broadhead, P., & Luft, H. S. (2004) Strategies To Support Quality-based Purchasing: A Review of the Evidence. Rockville (MD). Eijkenaar, F. (2012). Pay for performance in health care: an international overview of initiatives. Med Care Res Rev, 69(3), 251-276. doi: 10.1177/1077558711432891 Eijkenaar, F., Emmert, M., Scheppach, M., & Schoffski, O. (2013). Effects of pay for performance in health care: a systematic review of systematic reviews. Health Policy, 110(2-3), 115-130. doi: 10.1016/j.healthpol.2013.01.008 Emmert, M., Eijkenaar, F., Kemter, H., Esslinger, A. S., & Schoffski, O. (2012). Economic evaluation of pay-for-performance in health care: a systematic review. Eur J Health Econ, 13(6), 755-767. doi: 10.1007/s10198-011-0329-8 Enarson, D. R., HL; Arnadottir, T. (1994). Tuberculosis guide for low income countries. Paris: International Union Against Tuberculosis and Lung Disease. Foley, M. (2008). A Mixed Public-Private System for 2020 Retrieved from http://www.health.gov.au/internet/nhhrc/publishing.nsf/Content/16F7A93D8F578DB4CA2574D7001830E9/$File/A%20Mixed%20Public-Private%20System%20for%202020%20(M%20Foley).pdf Frieden, T. R., Fujiwara, P. I., Washko, R. M., & Hamburg, M. A. (1995). Tuberculosis in New York City--turning the tide. N Engl J Med, 333(4), 229-233. doi: 10.1056/NEJM199507273330406 Glickman, S. W., & Peterson, E. D. (2009). Innovative health reform models: pay-for-performance initiatives. American Journal of Managed Care, 15(10 Suppl), S300-305. Greene, S. E., & Nash, D. B. (2009). Pay for performance: an overview of the literature. Am J Med Qual, 24(2), 140-163. doi: 10.1177/1062860608326517 Harrison, M. J., Dusheiko, M., Sutton, M., Gravelle, H., Doran, T., & Roland, M. (2014). Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal study. BMJ, 349, g6423. doi: 10.1136/bmj.g6423 Hood, R. G. (2007). Pay-for-performance--financial health disparities and the impact on healthcare disparities. J Natl Med Assoc, 99(8), 953-958. Institute of Medicine (U.S.). Committee on Quality of Health Care in America. (2001). Crossing the quality chasm : a new health system for the 21st century. Washington, D.C.: National Academy Press. Institute of Medicine (U.S.). Committee on Redesigning Health Insurance Performance Measures Payment and Performance Improvement Programs., & ebrary Inc. (2007). Rewarding provider performance aligning incentives in Medicare Pathways to quality health care. (pp. xxi, 248 p.). Retrieved from http://site.ebrary.com/lib/ntu/Doc?id=10160738 Iseman, M. D., Albert, R., Locks, M., Raleigh, J., Sutton, F., & Farer, L. S. (1980). American Thoracic Society. Medical Section of the American Lung Association. Guidelines for short-course tuberculosis chemotherapy. Am Rev Respir Dis, 121(3), 611-614. Jha, A. K., Joynt, K. E., Orav, E. J., & Epstein, A. M. (2012). The long-term effect of premier pay for performance on patient outcomes. N Engl J Med, 366(17), 1606-1615. doi: 10.1056/NEJMsa1112351 Kang, H. Y., Wang, X. R., Wang, L. L., Wang, C., Cen, J., Gao, L., . . . Yu, L. (2010). [Clinical significance of zo-1 and id4 gene abnormal methylation in multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 18(5), 1192-1197. Khan, M. A. (2005). Achieving the Millennium Development Goals: The Public/Private Mix Geneva: World Health Organization. Kohn, L. T., Corrigan, J., & Donaldson, M. S. (2000). To err is human : building a safer health system. Washington, D.C.: National Academy Press. Kristensen, S. R., Meacock, R., Turner, A. J., Boaden, R., McDonald, R., Roland, M., & Sutton, M. (2014). Long-term effect of hospital pay for performance on mortality in England. N Engl J Med, 371(6), 540-548. doi: 10.1056/NEJMoa1400962 Kuo, R. N., Chung, K. P., & Lai, M. S. (2011). Effect of the pay-for-performance program for breast cancer care in Taiwan. American Journal of Managed Care, 17(5 Spec No), e203-211. Lee, C.-Y. (2010). Can insurance finance chronic care and disease control? Collaboration between NTP and national health insurance in Taiwan. Paper presented at the 41st Union World Conference on Lung Health, Berlin, Germany. Lee, T. T., Cheng, S. H., Chen, C. C., & Lai, M. S. (2010). A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. American Journal of Managed Care, 16(1), 65-69. Levine, S., Reyes, J., Schwartz, R., Schmidt, D., Schwab, T., & Leung, M. (2006). Disease management of the frail elderly population. Disease Management & Health Outcomes, 14(4), 235-244. Li, Y. H., Su, Z., Ma, H. M., Chen, H. S., Gu, Y. F., & Du, M. L. (2010). [Diagnostic value of serum levels of beta-human chorionic gonadotropin (beta-hcG) combined with beta-hcG in cerebrospinal fluid for determining locations of germinomas in children with precocious puberty]. Zhonghua Er Ke Za Zhi, 48(10), 771-774. Li, Y. H., Tsai, W. C., Khan, M., Yang, W. T., Lee, T. F., Wu, Y. C., & Kung, P. T. (2010). The effects of pay-for-performance on tuberculosis treatment in Taiwan. Health Policy Plan, 25(4), 334-341. doi: 10.1093/heapol/czq006 Ling, D. L., Liaw, Y. P., Lee, C. Y., Lo, H. Y., Yang, H. L., & Chan, P. C. (2011). Contact investigation for tuberculosis in Taiwan contacts aged under 20 years in 2005. Int J Tuberc Lung Dis, 15(1), 50-55. Lo, H. Y., Chou, P., Yang, S. L., Lee, C. Y., & Kuo, H. S. (2011). Trends in tuberculosis in Taiwan, 2002-2008. J Formos Med Assoc, 110(8), 501-510. doi: 10.1016/S0929-6646(11)60076-4 Lo, H. Y., Suo, J., Chang, H. J., Yang, S. L., & Chou, P. (2011). Risk Factors Associated With Death in a 12-Month Cohort Analysis of Tuberculosis Patients: 12-Month Follow-up After Registration. Asia Pac J Public Health. doi: 10.1177/1010539511429591 Lo, H. Y., Yang, S. L., Chou, P., Chuang, J. H., & Chiang, C. Y. (2011). Completeness and timeliness of tuberculosis notification in Taiwan. BMC Public Health, 11, 915. doi: 10.1186/1471-2458-11-915 Lonnroth, K., Thuong, L. M., Linh, P. D., & Diwan, V. K. (2001). Utilization of private and public health-care providers for tuberculosis symptoms in Ho Chi Minh City, Vietnam. Health Policy Plan, 16(1), 47-54. Lonnroth, K., Uplekar, M., Arora, V. K., Juvekar, S., Lan, N. T. N., Mwaniki, D., & Pathania, V. (2004). Public-private mix for DOTS implementation: what makes it work? Bulletin of the World Health Organization, 82(8), 580-586. Malmborg, R., Mann, G., & Squire, S. B. (2011). A systematic assessment of the concept and practice of public-private mix for tuberculosis care and control. Int J Equity Health, 10(1), 49. doi: 10.1186/1475-9276-10-49 Murray, C. J. L., Dejonghe, E., Chum, H. J., Nyangulu, D. S., Salomao, A., & Styblo, K. (1991). Cost-Effectiveness of Chemotherapy for Pulmonary Tuberculosis in 3 Sub-Saharan African Countries. Lancet, 338(8778), 1305-1308. Pathania V, A. J., Kochi A. (1997). TB patients and private for profit health care providers in India. http://whqlibdoc.who.int/hq/1997/WHO_TB_97.223.pdf Petersen, L. A., Woodard, L. D., Urech, T., Daw, C., & Sookanan, S. (2006). Does pay-for-performance improve the quality of health care? Annals of Internal Medicine, 145(4), 265-272. Phillips, C. (2009). What is cost effectiveness? Retrieved May 21, 2012, from http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/Cost-effect.pdf Pink, G. H., Brown, A. D., Studer, M. L., Reiter, K. L., & Leatt, P. (2006). Pay-for-performance in publicly financed healthcare: some international experience and considerations for Canada. Healthc Pap, 6(4), 8-26. Qiu, M. Z., Wang, Z. Q., Luo, H. Y., Zhang, D. S., Zhou, Z. W., Li, Y. H., . . . Xu, R. H. (2011). Prognostic analysis in node-negative gastric cancer patients in China. Tumour Biol, 32(3), 489-492. doi: 10.1007/s13277-010-0142-5 Qiu, M. Z., Wang, Z. Q., Zhang, D. S., Luo, H. Y., Zhou, Z. W., Wang, F. H., . . . Xu, R. H. (2011). Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. Tumour Biol, 32(3), 509-514. doi: 10.1007/s13277-010-0145-2 Robinson, J. C. (2001). Theory and practice in the design of physician payment incentives. Milbank Q, 79(2), 149-177, III. Rosenthal, M. B., Fernandopulle, R., Song, H. R., & Landon, B. (2004). Paying for quality: providers' incentives for quality improvement. Health Aff (Millwood), 23(2), 127-141. Rosenthal, M. B., & Frank, R. G. (2006). What is the empirical basis for paying for quality in health care? Medical Care Research and Review, 63(2), 135-157. doi: Doi 10.1177/1077558705285291 Rosenthal, M. B., Frank, R. G., Li, Z., & Epstein, A. M. (2005). Early experience with pay-for-performance: from concept to practice. JAMA, 294(14), 1788-1793. doi: 10.1001/jama.294.14.1788 Rosenthal, M. B., Landon, B. E., Normand, S. L., Frank, R. G., & Epstein, A. M. (2006). Pay for performance in commercial HMOs. N Engl J Med, 355(18), 1895-1902. doi: 10.1056/NEJMsa063682 RUBIN, P. R. R. a. D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41-55. Saint-Lary, O., Plu, I., & Naiditch, M. (2012). Ethical issues raised by the introduction of payment for performance in France. J Med Ethics, 38(8), 485-491. doi: 10.1136/medethics-2011-100159 Schatz, M. (2008a). Does pay-for-performance influence the quality of care? Current Opinion in Allergy and Clinical Immunology, 8(3), 213-221. Schatz, M. (2008b). Does pay-for-performance influence the quality of care? Curr Opin Allergy Clin Immunol, 8(3), 213-221. doi: 10.1097/ACI.0b013e3282fe9d1a Shan, G. Z., Peng, Z. G., Li, Y. H., Li, D., Li, Y. P., Meng, S., . . . Li, Z. R. (2011). A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure-activity relationships and anti-HCV activity in GS4.3 replicon cells. J Antibiot (Tokyo), 64(2), 177-182. doi: 10.1038/ja.2010.161 Small, P. M., Hopewell, P. C., Singh, S. P., Paz, A., Parsonnet, J., Ruston, D. C., . . . Schoolnik, G. K. (1994). The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med, 330(24), 1703-1709. doi: 10.1056/NEJM199406163302402 Steel, N., & Willems, S. (2010). Research learning from the UK Quality and Outcomes Framework: a review of existing research. Qual Prim Care, 18(2), 117-125. Town, R., Kane, R., Johnson, P., & Butler, M. (2005). Economic incentives and physicians' delivery of preventive care: a systematic review. Am J Prev Med, 28(2), 234-240. doi: 10.1016/j.amepre.2004.10.013 Tsai, W. C., Kung, P. T., Khan, M., Campbell, C., Yang, W. T., Lee, T. F., & Li, Y. H. (2010). Effects of pay-for-performance system on tuberculosis default cases control and treatment in Taiwan. J Infect, 61(3), 235-243. doi: 10.1016/j.jinf.2010.06.016 Uplekar, M. (2003). Involving private health care providers in delivery of TB care: global strategy. Tuberculosis, 83(1-3), 156-164. doi: 10.1016/S1472-9792(02)00073-2 Uplekar, M., Pathania, V., & Raviglione, M. (2001). Private practitioners and public health: weak links in tuberculosis control. Lancet, 358(9285), 912-916. Van Herck, P., De Smedt, D., Annemans, L., Remmen, R., Rosenthal, M. B., & Sermeus, W. (2010). Systematic review: Effects, design choices, and context of pay-for-performance in health care. Bmc Health Services Research, 10, 247. doi: 10.1186/1472-6963-10-247 Wang, D., Li, Y. H., Wang, Y. P., Gao, R. M., Zhang, L. H., & Ye, X. S. (2011). Synthesis and in vitro anti-hepatitis B virus activity of six-membered azanucleoside analogues. Bioorg Med Chem, 19(1), 41-51. doi: 10.1016/j.bmc.2010.11.063 Wang, L., Zhang, H., Ruan, Y., Chin, D. P., Xia, Y., Cheng, S., . . . Wang, Y. (2014). Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet, 383(9934), 2057-2064. doi: 10.1016/S0140-6736(13)62639-2 Weinstein, M. C., Siegel, J. E., Gold, M. R., Kamlet, M. S., & Russell, L. B. (1996). Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA, 276(15), 1253-1258. Weis, S. E., Slocum, P. C., Blais, F. X., King, B., Nunn, M., Matney, G. B., . . . Foresman, B. H. (1994). The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med, 330(17), 1179-1184. doi: 10.1056/NEJM199404283301702 Wen, C. P., Tsai, S. P., & Chung, W. S. (2008). A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Annals of Internal Medicine, 148(4), 258-267. Werner, R. M., & Dudley, R. A. (2009). Making the 'pay' matter in pay-for-performance: implications for payment strategies. Health Aff (Millwood), 28(5), 1498-1508. doi: 10.1377/hlthaff.28.5.1498 WHO. (1994a). TB: A Global Emergency. Retrieved May 21, 2012, from http://whqlibdoc.who.int/hq/1994/WHO_TB_94.177.pdf WHO. (1994b). WHO tuberculosis programme: framework for effective tuberculosis control. Retrieved May 21, 2012, from http://whqlibdoc.who.int/hq/1994/WHO_TB_94.179.pdf WHO. (1997). WHO calls for immediate use of new tuberculosis breakthrough (Vol. 2012). Geneva: World Health Organization. WHO. (1998). TB: a crossroads. WHO report on the global tuberculosis epidemic, 1998. Retrieved May 21, 2012, from http://whqlibdoc.who.int/hq/1998/WHO_TB_98.247.pdf WHO. (2003). Public-Private Mix for DOTS - Practical tools to help implementation (Vol. 2003). Geneva. WHO. (2008). An expanded DOTS framework for effective tuberculosis control. Retrieved May 21, 2012, from http://www.who.int/entity/tb/publications/expanded_dots_framework/en/index.html WHO. (2011). Global Tuberculosis Control 2011. Geneva: World Health Organization. WHO. (2012). Tuberculosis Key Facts. Retrieved May 21, 2012, from http://www.who.int/mediacentre/factsheets/fs104/en/index.html World Health Organization. (2013). CHOosing Interventions that are Cost Effective (WHO-CHOICE). Retrieved July 3, 2013, 2013, from http://www.who.int/choice/costs/CER_thresholds/en/ World Health Organization. (2006). Engaging all Health Care Providers in TB Control: Guidance on Implementing Public-Private Mix Approaches. Geneva: WorldHealthOrganization. 行政院衛生署. (2004). 新修正結核病醫療給付改善方案新聞稿. Retrieved May 21, 2012, from http://www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_no=25&now_fod_list_no=5913&level_no=2&doc_no=22926 行政院衛生署. (2010). 全民有健保 健康沒煩惱Part 1 -有品質的健康照護. Retrieved May 21, 2012, from http://health99.doh.gov.tw/Article/ArticleDetail.aspx?TopIcNo=617&DS=1-life 索任. (2008). 台灣防癆工作的今昔. 疫情報導, 24(3), 169-176. 健保局. (2002). Introduction of 5 Pay for Performance Programs in Taiwan. National Health Insurance Bimonthly Journal, 35, Hot Topics. 健保局. (2003). Five pay for performance programs preliminary outcomes. National Health Insurance Bimonthly Journal, 44, Hot Topics. 健保局. (2012). 全民健保醫療給付改善方案制度簡介. Retrieved May 21, 2012, from http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&menu_id=659&WD_ID=897&webdata_id=4031 許建邦 羅秀雲 李政益, 楊祥麟., 王貴鳳, 楊世仰. (2008). 台灣都治(DOTS)執行經驗及成效初探. 疫情報導, 24(3), 184-203. 楊志良. (2011). 照顧弱勢、落實庶民經濟-健保費率依法調整建議方案. Retrieved May 21, 2012, from http://www.nhi.gov.tw/Resources/news/376_健保費率依法調整建議方案.pdf 楊銘欽. (2006). 衛生醫療業務成本及效益評估基本規範與實際案例研究. Retrieved May 21, 2012, from http://www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_no=4&now_fod_list_no=6224&level_no=1&doc_no=47266 詹珮君. (2011). 接觸結核病人後可以做的事. 台灣防癆雜誌, 2011(Summer). 衛生署疾病管制局. (2011a). 台灣結核病防治年報 2010. 台北: 衛生署疾病管制局. 衛生署疾病管制局. (2011b). 結核病診治指引(第四版). 台北: 衛生署疾病管制局. 聯合報. (2009). 克魯曼推薦 台灣健保真的好. Retrieved May 21, 2012, from http://mag.udn.com/mag/world/storypage.jsp?f_ART_ID=193139 謝鈺婷, 管中閔., 蔡蕙安,謝釭偉. (2010). 評估健保制度中肺結核的論質計酬專案. 人文及社會科學集刊, 22(4), 485-519. 羅秀雲 李政益 楊祥麟, 莊人祥., 張峰義. (2012). 傳染病與國家競爭力. 台灣公共衛生雜誌, 31(2), 97-104. 蘇秋霞, 張庸敏. (2007). 金門縣結核病都治前驅計畫成效分析. 疫情報導, 23(2), 61-71. 鐘威昇. (2008). 台灣肺結核都治計畫的經濟評估. (博士論文), 台灣大學醫療機構管理研究所, 台北市. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4881 | - |
dc.description.abstract | 背景:為解決結核病防治的困境,提供完整個案照護、提升醫療品質,衛生福利部疾病管制署與健保署於2001年試辦執行「論質計酬」(Pay for Performance, P4P),2004年擴大執行;之後疾病管制署亦於2006年全面推動「都治計畫」(Directly Observed Treatment, Short-course, DOTS)。
目的:一、評估我國執行結核病論質計酬方案成效,分析加入方案與否其治療結果與醫療利用的差異。二、進行結核病論質計酬方案以及結核病都治計畫成本效果評估。 方法:一、研究採2004年結核病通報確診之法定個案(N=15,557),並串連健保資料庫以瞭解其醫療利用情形。針對加入與未加入P4P之個案,採傾向分數配對法(Propensity Score Matching)以提高兩組間可比較性,並利用多變項迴歸模型以瞭解P4P方案之效果。二、採2006-2007年結核病通報確診之法定個案,並符合第一階段都治執行之痰抹片陽性個案(N=10,766),串連健保資料庫,以分析其醫療利用(直接成本);搭配行政院主計總處人力資源調查資料庫,依該年度結核病個案特質,分別計算社會生產力以及陪病家屬生產力損失(間接成本),並以社會觀點呈現總成本支出。 結果:一、加入P4P方案與否兩組病人特性無統計顯著差異。P4P個案門診利用頻次較未加入者高14%(P<0.001),但住院、急診頻率則無統計上之差異。P4P總醫療成本比未加入者少4.6%(新台幣6,450元);治療成功勝算比,為未加入者之1.56(OR:1.38-1.76, P<0.001),死亡率亦低3.9%。二、同時加入P4P與DOTS者,比起僅加入P4P、DOTS、皆未加入組,同時加入組病況較嚴重,但治療成功比例最高(83.1%),皆未加入方案者最低(24.2%)。以直接成本(含醫療利用與都治計畫)而言,皆未加入組平均成本新台幣66,707元最低;同時加入P4P與DOTS者平均成本新台幣93331最高。以社會觀點成本(加計社會生產力損失與陪病成本等)而言,皆未加入組平均成本新台幣83,767元最低;同時加入P4P與DOTS者平均成本新台幣109,266最高。如以平均成本效果比(Average Cost-Effectiveness Ratio , ACER)而言,P4P(121,335元)、DOTS(171,226元)、P4P+DOTS(131,530元)以及常規治療方案(346,187元);加入P4P平均每名治療成功個案所需耗費的成本最低。多元方案比較,利用增量成本效果比(Incremental Cost-Effectiveness Ratio, ICER)進行分析,加入P4P為最具成本效果比之方案。若以世界衛生組織評估衛生政策介入是否具成本效果之基準(WHO-CHOICE, CHOosing Interventions that are Cost-Effective),利用ACER進行方案評估後,各方案皆小於1 GDP per capita,皆為高度成本效果比(Highly cost-effective)之介入方案。 結論:一、P4P方案可提高照護結果,並節省整體醫療費用。二、同時加入P4P與DOTS者,其治療結果最佳,以社會層面觀點(societal perspective)考量直接成本以及間接成本而言,加入P4P方案平均耗費成本最低。利用世界衛生組織評估標準,P4P、DOTS皆為高度成本效果之介入措施。 | zh_TW |
dc.description.abstract | Background: Taiwan Centers for Disease Control (CDC) and Bureau of National Health Insurance (BNHI) implemented the tuberculosis (TB) pay-for-performance (P4P) program in 2001 to improve health care qualities and case management, and which program was broadly adopted in 2004. A nationwide campaign “Directly Observed Treatment, Short-course” (DOTS) was then introduced in 2006.
Objectives: The objective of the study was to evaluate the efficacy of TB P4P program, and to explore treatment outcomes and health care utilizations. The other purpose was cost-effectiveness analysis of P4P and DOTS programs. Methods: This study recruited 15,557 TB cases who were reported to the Taiwan CDC in 2004, and then linked with health care utilization claimed data from BNHI. To improve the comparability of the two groups, we used Propensity Score Matching to compare the performance between cases with and without P4P program, and also used multinomial logistic regression model to investigate the efficacy of P4P. In the other part of the study, the study recruited 10,766 cases diagnosed in 2006-2007 and eligible for DOTS stage I (sputum smear positive cases). Data linking to BNHI was to analyze the medical utilization (direct costs). To explore social productivity loss of patients and family members, we used data from Directorate-General of Budget, Accounting and Statistics survey of human resources database to explore the indirect costs, and the study represented societal perspective costs. Results: The results showed that no significant difference in case characteristics between two groups with and without P4P program. The study revealed that P4P group had a higher Outpatient Department (OPD) utilization rate of 14% (P<0.001), but no significance in hospital admission or emergency utilization. Total medical costs in P4P group were 4.6% lower (NTD. 6,450; USD. $215) than non-P4P group. Odds Ratio of treatment success was 1.56 times higher than non-P4P group. (OR: 1.38-1.76, P<0.001). Death rate in the P4P group was 3.9% lower than non-P4P group. Comparing group with P4P and DOTS, group with P4P only, group with DOTS only, and group without P4P or DOTS, P4P and DOTS group had inferior medical conditions, but had the highest treatment success rate (83.1%), group without P4P or DOTS had the lowest treatment success rates of 24.2%. Regarding to the direct costs, average cost of group without P4P or DOTS were the lowest (NTD. 66,707; USD. $2223.6), while of P4P and DOTS group were the highest (NTD. 93,331; USD. $3111.0). As for societal perspective costs, including loss of social productivity of patients and family member companions, group without P4P or DOTS had the lowest average costs of NTD. 83,767 (USD. $2,792.3), whereas P4P and DOTS group had the highest of NTD. 109,266 (USD. $3,642.2). As for Average Cost-effectiveness Ratio (ACER), P4P group was NT121,335 (USD. $4,044.5), DOTS group as NT171,226 (USD. $5,707.5), P4P and DOTS group as NT131,530 (USD. $4,384.3), and conventional TB treatment was NT346,187 (USD. $11,539.6) . Overall, P4P group had the lowest expenditures of per treatment success case. Comparing with multiple programs, we adopted Incremental Cost-Effectiveness Ratio (ICER), the P4P was the most cost-effective program. According to WHO-CHOICE (CHOosing Interventions that are Cost-Effective), adopting ACER to evaluate programs, P4P and DOTS programs were all highly cost-effective interventions. Conclusion: The TB P4P program can improve health care outcomes, and save the health care expenditure. Secondly, patients enrolled both in P4P and DOTS programs, had the best treatment outcomes. Considering direct and indirect costs in societal perspective, P4P program costs the lowest with average. P4P and DOTS programs are both highly cost-effective intervention programs according to the World Health Organization standard (WHO-CHOICE, CHOosing Interventions that are Cost-Effective). | en |
dc.description.provenance | Made available in DSpace on 2021-05-14T17:49:30Z (GMT). No. of bitstreams: 1 ntu-104-D95845002-1.pdf: 2128797 bytes, checksum: d32456db852250c3b955a74d82e2b906 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員會審定書i
中文摘要 iii Abstract v 第一章 緒論 1 第一節 研究背景 1 第二節 問題現況 2 防治缺乏整合與多重抗藥性結核病的出現 2 健保開辦民眾就醫方便,但造成防治挑戰 3 第三節 結核病防治與論質計酬制度的應用 5 第四節 結核病都治計畫緣起與台灣之推動 8 第五節 研究目的 14 第二章 文獻探討 16 第一節 台灣結核病流行情形與相關問題 16 第二節 論質計酬制度在國際上的研究發展 24 第三節 台灣在論質計酬制度上的應用與相關研究發展 38 第四節 都治計畫的研究發展 49 第五節 綜合評論 58 第三章 材料與方法 60 第一節 資料來源 60 結核病資料庫說明 60 全民健康保險資料庫 61 台灣都治計畫資料庫 62 行政院主計總處人力資源調查資料庫 63 第二節 研究對象 64 目的一:評估結核病論質計酬方案執行情形 64 目的二:論質計酬與都治計畫成本效果評估 64 第三節 研究設計 66 目的一:評估結核病論質計酬方案執行情形 66 目的二:論質計酬與都治計畫成本效果評估 67 第四節 研究假說 68 第五節 研究變項與定義 69 結核病個案定義 69 加入論質計酬方案定義 69 加入都治計畫定義 70 結核病治療結果定義 71 醫療服務利用定義 72 其他資料定義 72 第六節 資料分析 74 回溯性觀察分析 74 傾向分數配對法 75 成本效果評估 77 第四章 研究結果 82 第一節 評估結核病論質計酬方案執行情形 82 第二節 評估結核病論質計酬方案與都治計畫之成本效果分析 100 第五章 討論 118 第一節 評估結核病論質計酬方案執行情形 118 第二節 評估結核病論質計酬方案與都治計畫之成本效果分析 124 第三節 研究限制 132 第六章 結論與建議 134 第一節 結論 134 第二節 建議 136 參考文獻 138 附錄 台灣防癆體系的轉型再造與公私機構整合新契機 148 | |
dc.language.iso | zh-TW | |
dc.title | 全民健保論質計酬制度及都治計畫對結核病防治之成效評估 | zh_TW |
dc.title | Performance Evaluation of the Pay-for-Performance Program and Directly Observerd Treatment, Short-course for Tuberculosis Control | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張鴻仁,楊銘欽,張上淳,蔡憶文 | |
dc.subject.keyword | 結核病,論質計酬,都治計畫,成本效果分析,醫療利用, | zh_TW |
dc.subject.keyword | Tuberculosis,Pay for Performance (P4P),Directly Observed Treatment,Short-course (DOTS),Cost-Effectiveness Analysis,Health Care Utilization, | en |
dc.relation.page | 154 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2015-01-13 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf | 2.08 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。